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Abstract 
Objectives:  United Kingdom guidelines recommend screening for and treatment of 
latent tuberculosis infection (LTBI) in HIV-positive patients at high risk of active 
tuberculosis disease (TB), but implementation is sub-optimal. We investigated potential 
missed opportunities to identify and treat LTBI among HIV-positive patients accessing a 
large HIV outpatient service in London. 
 
Methods: Case records of all adult patients attending our service for HIV care diagnosed 
with active TB between 2011 and 2015 were reviewed, to determine whether they met 
criteria for LTBI screening and whether screening was undertaken.  
 
Results: Twenty-five patients were treated for TB. Of 15 (60%) patients who started TB 
treatment ≥six months after HIV diagnosis, 14 (93%) met UK guideline-recommended 
criteria for LTBI screening and treatment; only one (7%) had been screened for LTBI. 
Eight of these 15 (53%) patients had additional risk factors for TB which are not 
reflected in current UK guidelines.  
 
Conclusions: Of 15 patients treated for TB ≥six months after diagnosis of HIV, 14 (93%) 
had not been screened for LTBI, suggesting missed opportunities for TB prevention. 
People living with HIV may benefit from a broader approach to LTBI screening which 
takes into account additional recognised TB risk factors and ongoing TB exposure. 
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Background 
People living with HIV are at high risk of developing active tuberculosis (TB)1.  Screening 
for and treatment of latent TB infection (LTBI) in selected HIV patients is effective and 
cost-effective2,3 and is recommended by the British HIV Association (BHIVA) for patients 
at high risk of TB reactivation, defined by CD4 count, duration of antiretroviral therapy 
(ART) and TB incidence of their region of origin4 (Table 1). However, a recent evaluation 
found that only 57.4% of UK geographical areas offer screening5. 
 
Table 1. Summary of British HIV Association 2011 guidelines for screening and treatment 
of latent tuberculosis infection in HIV-infected persons4 
Tuberculosis prevalence of region of 
origin*  
Criteria for latent tuberculosis screening 
according to British HIV Association 
guidelines 
Recommendation if 
criteria are met 
Low (including UK, Western Europe, 
Australia, USA, Canada and New Zealand) 
On ART for less than 6 months and 
CD4<350 
Screen for latent 
tuberculosis infection 
using interferon-
gamma release assay 
and provide chemo-
preventative therapy if 
positive 
Medium (including Eastern Europe, 
Central Asia, North Africa and the Middle 
East, South Asia, East Asia and the 
Caribbean) 
On ART for less than 2 years and CD4<500 
High (sub-Saharan Africa) On ART for less than 2 years 
 
ART: antiretroviral therapy; UK: United Kingdom; USA: United States of America 
*Numerical definitions of “low”/ “medium”/ “high” incidence not included in the guidelines 
 
 
In our UK HIV clinic, 33% of patients originate from high- or medium-TB incidence 
regions. We introduced a policy of LTBI screening and treatment according to BHIVA 
guidelines in 2011, but an audit in 2015 revealed only 12.1% screening completion6. We 
retrospectively reviewed case notes of HIV patients diagnosed with TB, to investigate 
whether there were missed opportunities to identify and treat LTBI. 
 
Methods 
Adults (≥18 years) attending our service for HIV care and diagnosed with TB in 2011-
2015 were included. TB cases were identified from the Public Health England London TB 
Register and from our microbiology service’s database. Patients were classified into two 
groups according to the time between HIV diagnosis and TB treatment start date: 
“early” (less than six months), or “late” (six months or more), assuming that TB episodes 
starting less than six months after HIV diagnosis probably could not have been averted 
by screening and treatment of LTBI. We compared our clinic practice with 2011 BHIVA 
guidance4. 
 
Results 
We identified 25 patients diagnosed with TB between 2011 and 2015 (Table 2). Twelve 
(48%) were from high-, four (16%) from medium-, and nine (36%) from low-TB incidence 
regions of origin. Time between HIV diagnosis and TB treatment start date ranged from -
5 days to 27 years. Ten (40%) had TB "early" (less than six months after HIV diagnosis).  
 
Table 2. Characteristics of HIV-positive individuals with tuberculosis 
Group Early Late 
Time between HIV diagnosis and TB episode <6 months (N=10) ≥6 months (N=15) 
Time between HIV diagnosis and TB episode, median (range) 10.5 days 
(-5-125 days) 
4.6 years 
(1.1-26.9 years) 
Male, n (%) 5 (50%) 10 (67%) 
Age (years), median (range) 47 (24-56) 42 (29-59) 
Risk 
factors for 
TB 
infection 
Region of 
origin* 
Low TB incidence 2 (20%) 7 (47%) 
Medium TB incidence 2 (20%) 2 (13%) 
High TB incidence 6 (60%) 6 (40%) 
Other TB 
risk 
factors 
Extensive travel/residence in high-
incidence area 
1 (10%) 2 (13%) 
TB contact 0 (0%) 3 (20%) 
Healthcare worker 1 (10%) 2 (13%) 
Intravenous drug use 0 (0%) 2 (13%) 
Previous/current prison resident 0 (0%) 2 (13%) 
Homelessness 1 (10%) 1 (7%) 
At least one of these “other” risk 
factors 
3 (30%) 8 (53%) 
At least one of these risk factors for TB infecMon† 9 (90%) 12 (80%) 
CD4 cell count at start of TB episode (cells/mm3), median (range) 110 (0-310) 480 (20-570) 
On antiretroviral therapy at start of TB episode 3 (30%) 6 (40%) 
Diagnosed with TB during/following an inpatient admission 9 (90%) 9 (60%) 
TB: Tuberculosis 
*Definitions of low, medium and high incidence follow British HIV Association guidance4 
†Includes high- or medium-TB incidence region of origin, and additional risk factors listed in the table. Several 
patients had more than one risk factor.  
 
“Early” TB 
Of ten patients, eight (80%) were from medium- or high-TB incidence regions. At TB 
diagnosis median CD4 was 110 (range 0-310) cells/mm3. Nine (90%) were diagnosed 
with TB during or following inpatient admissions. Eight (80%), all from medium- or high-
incidence regions, had TB symptoms at the time of HIV diagnosis. The remaining two 
developed “unmasking” immune reconstitution inflammatory syndrome following ART 
initiation. 
“Late” TB 
Of 15 patients, 53% were from high- or medium-TB incidence regions. Additionally, nine 
(60%) had at least one other recognised TB risk factor, such as healthcare work or time 
spent in prison (Table 2). Six (40%) were on ART at the time of TB diagnosis, for a 
median of 2.6 years (range 219 days-9.9 years), all virologically suppressed. Median CD4 
count was 480 (range 20-570) cells/mm3. Nine (60%) were diagnosed during or following 
an inpatient admission. 14 (93%) patients successfully completed TB therapy, but one 
died of disseminated TB. 
Missed opportunities for LTBI diagnosis and treatment 
Of the “late” TB group, 14 (93%) met criteria for LTBI screening and treatment at some 
point following HIV diagnosis. The individual who did not was from a low-incidence 
region but did have other TB risk factors (extensive travel to high-incidence countries 
and previous imprisonment). Only one had LTBI screening performed. He had a negative 
Quantiferon Gold interferon-gamma release assay (IGRA) one month after HIV 
diagnosis, when his CD4 was 60 cells/mm3; he remained at potential risk of TB exposure 
after screening. He was diagnosed with culture-positive pleural TB one year later.  
 
Discussion 
In our HIV service, TB continues to cause morbidity (72% inpatient admission rate) and 
occasionally mortality. Despite most patients who developed “late” TB meeting the 
2011 BHIVA criteria for LTBI screening, most were not screened (in keeping with our 
previous audit6). Prompts have been included in the electronic patient record to 
promote LTBI screening, but our impression is that these remain underutilised. One 
potential barrier to clinicians initiating screening is that the 2011 BHIVA guidelines are 
complex, requiring integration of information about CD4, ART history and region of 
origin. The 2017 draft BHIVA guidelines recommend a simplified approach which may be 
easier to implement7. 
 
Many patients, including the one who did not otherwise meet screening criteria, had 
additional risk factors for TB infection, suggesting that selection of patients for LTBI 
screening may need to take account of risk factors beyond HIV stage and region of 
origin. This is the approach taken by the 2017 draft guideline7.  
 
Even with increased LTBI screening at enrolment in HIV care, it is unlikely that all “late” 
cases of TB were preventable. IGRA sensitivity for LTBI is not 100%8. Furthermore, some 
patients developed TB many years after their HIV diagnosis, and/or had risk factors 
suggesting ongoing TB exposure, which may require different strategies.  
 
Several patients had inconsistent concordance with care, and might not have taken 
preventative therapy even if offered; although TB preventative treatment does confer 
additional benefits to ART alone, optimising HIV treatment in this group might also have 
reduced TB incidence9,10,11. While beyond the scope of this audit, earlier HIV diagnosis 
might also have averted TB morbidity for the eight (32%) patients whose TB and HIV 
diagnoses were essentially simultaneous (less than a two-month interval), and who all 
had CD4<350 at diagnosis. 
 
Conclusions 
There are missed opportunities for LTBI screening in our HIV service, and improving 
coverage of those at highest risk could reduce morbidity and mortality. People living 
with HIV may benefit from an approach to LTBI screening which incorporates broader TB 
risk factors and ongoing TB exposure.  
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